Eli Lilly and Company (NYSE:LLY) Shares Sold by West Oak Capital LLC

West Oak Capital LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 5,842 shares of the company’s stock after selling 855 shares during the period. Eli Lilly and Company makes up 1.0% of West Oak Capital LLC’s holdings, making the stock its 8th largest position. West Oak Capital LLC’s holdings in Eli Lilly and Company were worth $5,176,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in LLY. Capital Planning LLC bought a new stake in Eli Lilly and Company in the first quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $6,916,000. M&G Plc acquired a new stake in Eli Lilly and Company during the 1st quarter worth $8,896,000. BTC Capital Management Inc. bought a new position in Eli Lilly and Company during the first quarter worth about $1,432,000. Finally, High Net Worth Advisory Group LLC lifted its holdings in Eli Lilly and Company by 1.4% during the first quarter. High Net Worth Advisory Group LLC now owns 4,919 shares of the company’s stock worth $3,827,000 after acquiring an additional 67 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $917.86 on Friday. The company has a market cap of $872.34 billion, a PE ratio of 135.18, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The firm has a 50-day moving average of $921.21 and a 200-day moving average of $857.37. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on LLY shares. Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $986.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.